Study on Efficacy and Safety of Human Albumin in Burn Shock Recovery

Study Overview
=================
Brief Summary
-----------------
To explore the effects and safety of human albumin in burn shock recovery, and then provide a theoretical basis for its rational use.

Detailed Description
-----------------
A retrospective case-control study was conducted. Patients who admitted to the burn ward and needed fluid resuscitation during the period of January 2011 to December 2018 in our unit were identified. Patients were divided into two groups according to the severity of burns, the patients with a 20%<TBSA≤50% constituted the moderate and severe burn group, the patients with a TBSA>50% constituted the severest burn group, and then the patients who used albumin for resuscitation constituted the albumin group, the patients who did not use albumin constituted the control group. The primary outcome was mortality, and the secondary outcomes included hospital stay, ventilator supporting, fluid use, and complications.

Official Title
-----------------
Study on Efficacy and Safety of Human Albumin in Burn Shock Recovery

Conditions
-----------------
Burns Shock

Intervention / Treatment
-----------------
* Drug: Albumin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 TBSA≥ 20% （TBSA，the total burn area.） Admitted to hospital within 24 hours after injury. Exclusion Criteria: STB ≥ 33 μ mol/L Cr ≥ 171 μ Urine output l< 500 ml / 24 h Pregnant and lactating women Severe combined injury Glucocorticoids users Immunosuppressants users Patients survived less than 48 hours

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| the albumin group<br>The albumin group, the patients who used albumin for resuscitation during their hospitalization in the burn ward constituted the albumin group. | Drug: Albumin<br>* At least one dose of human albumin was used for the patients during hospitalization in the burn ward consisted the albumin group. The patients who have no albumin use during their hospitalization in the burn ward consisted the control group.<br>* Other names: human albumin;|
| the control group<br>The control group, the patients who did not use albumin during their hospitalization in the burn ward constituted the control group. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the mortality of the patients | The mortality of the patients during their hospitalization. | during the patients's hospitalization, an average of 1-2 month. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the length of the patients's hospital stay | the Length of the patients's hospital stay,an average of 1-2 month. | during the patients's hospitalization, an average of 1-2 month. | 
| the number of patients that using ventilators | the number of patients who using ventilators during their hospitalization | during the patients's hospitalization, an average of 1-2 month. | 
| Volume of fluid used for resuscitationVolume of fluid used for resuscitation the volume of the patients's resuscitation fluid | the volume of the patients's resuscitation fluid using mL as the measurement | during the patients's hospitalization, an average of 1-2 month. | 
| the number of complications that the patients occurred | the number of complications that the patients occurred during their hospitalization | during the patients's hospitalization, an average of 1-2 month. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
burns; shock; recovery; human albumin; effect